Piperlonguminine
(Synonyms: 荜茇宁) 目录号 : GC16166An alkaloid amide with anti-inflammatory properties
Cas No.:5950-12-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Piperlonguminine is an agent with anticancer, antihyperlipidemic, as well as anti-inflammatory properties.
Piperlonguminine is a bio-active isolate of Piper longum.
In vitro: In a previous study, piperlonguminine was discovered to inhibit melanin production in melanoma B16 cells stimulated with α-MSH, 3-isobutyl-1-methylxanthine or protoporphyrin IX, where piperlonguminine showed stronger depigmenting efficacy. However, piperlonguminine could not alter1-oleoyl-2-acetyl-sn-glycerol-induced melanogenesis and could not affect protein kinase C-mediated melanin production. In additioin, piperlonguminine was not able to inhibit the catalytic activity of cell-free tyrosinase from melanoma B16 cells, and such effect was attributed to the inhibitory action of piperlonguminine on α-MSH-induced signaling via cAMP to the cAMP responsive element binding protein [1].
In vivo: In vivo, rats were subjected to middle cerebral artery occlusion for 1h, followed by reperfusion for 23 h. The results showed that the intraperitoneal injection of piperlonguminine PE at 2.4 mg/kg was able to produce a significant neuroprotective potential in rats with cerebral ischemia. In addition, piperlonguminine could attenuate the neurological deficit scores, brain infarct volume and brain water content, and could inhibit the activation of NF-κB and MAPK [2].
Clinical trial: Up to now, piperlonguminine is still in the preclinical development stage.
References:
[1] Kim KS, Kim JA, Eom SY, Lee SH, Min KR, Kim Y. Inhibitory effect of piperlonguminine on melanin production in melanoma B16 cell line by downregulation of tyrosinase expression. Pigment Cell Res. 2006 Feb;19(1):90-8.
[2] Yang T, Sun S, Wang T, Tong X, Bi J, Wang Y, Sun Z. Piperlonguminine is neuroprotective in experimental rat stroke. Int Immunopharmacol. 2014 Dec;23(2):447-51.
| Cas No. | 5950-12-9 | SDF | |
| 别名 | 荜茇宁 | ||
| 化学名 | 5-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)-2E,4E-pentadienamide | ||
| Canonical SMILES | O=C(/C=C/C=C/C1=CC=C(OCO2)C2=C1)NCC(C)C | ||
| 分子式 | C16H19NO3 | 分子量 | 273.3 |
| 溶解度 | ≤3mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.659 mL | 18.2949 mL | 36.5898 mL |
| 5 mM | 0.7318 mL | 3.659 mL | 7.318 mL |
| 10 mM | 0.3659 mL | 1.8295 mL | 3.659 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。